CFO’s “Buy‑Now, Sell‑Later” Play at Capricor: Insider Confidence Amid Volatile Stock and FDA Countdown

Insider Activity at Capricor Therapeutics: A Closer Look

Capricor’s recent trading activity has attracted attention beyond the usual quarterly updates. On June 25, 2026, Chief Financial Officer (CFO) Bergmann Anthony executed a sizeable purchase of 24,100 shares at $3.18 each—well below the day’s closing price of $26.44—while simultaneously selling an equal number of shares at $30.38 via a 10(b)(5)(1) plan. The dual transaction reflects a common insider strategy: locking in gains at a high while acquiring more shares at a lower valuation. The CFO’s buy now, sell later approach aligns with a long‑term confidence in the company’s pipeline, especially given the pending July 29 FDA advisory committee meeting on Deramiocel.

What Does This Mean for Investors?

The CFO’s trade suggests that senior management remains bullish on Capricor’s future, even as the stock’s recent swing—down 18.9% this week, 18.2% this month, yet up 145% YTD—indicates volatility. The 10(b)(5)(1) sale reduces short‑term risk, while the fresh purchase bolsters ownership stake at a discount to the market. For investors, this duality can be interpreted as a confidence vote: management is willing to commit capital while also protecting against a potential short‑term decline. Market‑cap of $1.5 billion and a P/E of –12.76 underline the company’s high‑risk, high‑reward profile, typical for a clinical‑stage biotech.

CFO Bergmann Anthony: A Transaction Profile

Anthony’s historical filing record shows a pattern of alternating buys and sells at both low and high price points. Over the past year, he has executed 25 transactions involving over 200,000 shares, frequently using 10(b)(5)(1) plans to structure sales at favorable prices. He also routinely liquidates stock options and restricted units—often when they vest or reach a target price. This disciplined approach indicates a focus on risk‑management and long‑term value creation rather than speculative trading. The recent June 25 transaction fits that mold: a strategic acquisition at a low cost offset by a scheduled sale at a higher price.

Broader Insider Landscape

While the CFO’s activity dominates, other insiders such as EVP Karen Krasney have mirrored a similar pattern—buying large blocks at low prices and selling at higher ones. Together, these moves suggest that senior leadership collectively views Capricor’s trajectory favorably, even amid market fluctuations. For the broader shareholder base, the insider confidence can be a positive signal, particularly as the company heads toward critical FDA milestones that could unlock significant upside.

Bottom Line

Bergmann Anthony’s recent buy/sell combo reflects a calculated bet on Capricor’s pipeline, especially Deramiocel’s upcoming FDA review. For investors, the CFO’s actions signal a balanced risk‑reward stance: commitment to the company at a discount while protecting against near‑term volatility. Coupled with positive social‑media buzz and the company’s strong YTD performance, insiders’ confidence could serve as a catalyst for renewed investor interest, provided the clinical milestones materialize as scheduled.